Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Evotec has entered into a strategic advisory agreement for support in the development of Aspireo Pharmaceuticals' Somatoprim (DG3173).
Subscribe to our email newsletter
Somatoprim, which is currently in phase I of clinical development, is a new molecular entity somatostatin analogue which is proved in treating Acromegaly, carcinoid tumours, and Cushing’s disease, Diabetic Retinopathy.
Under the agreement, Evotec will provide Aspireo with strategic and operational advice on the partnering of Somatoprim.
In addition, Evotec will consult Aspireo on matters of clinical and pre-clinical development.
Evotec CEO Werner Lanthaler said, "This agreement marks a new business model for asset centric biotech companies who want to combine capital efficiency with access to high quality and often very specialised pre-clinical, clinical, regulatory and commercial expertise."
Aspireo CEO Carsten Dehning said the strategic advisory agreement comes at a time when the company is getting closer to reach clinical proof of concept for Somatoprim.
"Aspireo is combining the strengths of a project focused company with the benefits of accessing complete teams with leading expertise drug development and proven partnering skills," Dehning added.